{"schema_version":"secwatch.filing_event.v1","accession":"0001159036-25-000047","form_type":"8-K","ticker":"HALO","cik":"0001159036","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2025-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.904840+00:00","generated_at":"2026-05-17T00:11:13.760583+00:00","sec_items":["1.01","2.03","8.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Halozyme to offer $1.3B in convertible notes; extends credit facility to $750M","bullets":["Amended credit facility: commitments increased to $750M, maturity extended to Nov 5, 2030; no outstanding borrowings.","Proposes $650M 2031 notes and $650M 2032 notes; option for additional $100M each.","Net proceeds partly fund capped call transactions to reduce potential dilution upon conversion.","Plans to repurchase existing 0.25% 2027 and 1.00% 2028 convertible notes via private deals.","Remaining proceeds for general corporate purposes, including working capital and acquisitions."],"urls":{"canonical":"https://secwatch.observer/filing/0001159036-25-000047","json":"https://secwatch.observer/filing/0001159036-25-000047.json","markdown":"https://secwatch.observer/filing/0001159036-25-000047.md","text":"https://secwatch.observer/filing/0001159036-25-000047.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1159036/000115903625000047/0001159036-25-000047-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1159036/000115903625000047/halo-20251105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:11:13.760583+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}